id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2005-P-0366-0005,FDA,FDA-2005-P-0366,Citizen Petition from Keller and Heckman LLP on behalf of Biovail Corporation,Other,Citizen Petition,2010-03-17T04:00:00Z,2010,3,2010-03-17T04:00:00Z,,2025-04-24T18:52:49Z,,0,0,090000648044af2c
FDA-2005-P-0366-0006,FDA,FDA-2005-P-0366,Tab 2 - Summary Report of Study No. AK1BOVAIL2548 re: Citizen Petition from Keller and Heckman LLP on behalf of Biovail Corporation,Other,Background Material,2010-03-17T04:00:00Z,2010,3,2010-03-17T04:00:00Z,,2025-04-24T19:31:26Z,,0,0,090000648044af2f
FDA-2005-P-0366-0007,FDA,FDA-2005-P-0366,Letter from Keller and Heckman LLP to FDA DDM,Other,Letter(s),2010-03-17T04:00:00Z,2010,3,2010-03-17T04:00:00Z,,2025-04-24T19:33:22Z,,0,0,090000648044af44